9 June 2016
9-10 am EDT (15:00-16:00 CET)
The webinar will provide an update on the design, study start-up, study sites, and anticipated timeline of the endTB clinical trial, a Phase III trial, using Bayesian outcome-adapted randomization to examine 5 all-oral, 9-month regimens for MDR-TB. All regimens contain at least one of the newly approved anti-TB drugs, bedaquiline and delamanid. The trial is supported by UNITAID and will be implemented by MSF & PIH and their partners.
See below for instructions on how to connect via web conference. There will not be a dial-in option for this webinar.
To connect to the AdobeConnect meeting room, click or copy the following link into your browser: http://pih.adobeconnect.com/webinar/
Prior to the meeting, test your connection here: http://pih.adobeconnect.com/common/help/en/support/meeting_test.htm
To familiarize yourself with Adobe Connect and get a quick overview, see here: http://www.adobe.com/products/adobeconnect.html